A leading global private equity firm needed to validate a $500M medtech acquisition-fast. By combining EN++’s rapid expert calls with offshore research, they reduced due diligence time by 50% and gained the confidence to move ahead of competitors. Discover how modular, expert-led research transformed their investment process.
A leading global consulting firm needed to build a market entry strategy for a fintech client targeting Asia. EN++ delivered rapid, in-depth interviews and expert surveys, enabling the consulting team to validate hypotheses and craft a winning go-to-market plan-fast.
Launching a new pharmaceutical drug in emerging markets requires more than just regulatory approval—it demands a meticulously planned Go-To-Market (GTM) strategy to ensure physician adoption, hospital partnerships, and patient trust. A biotech firm with a breakthrough drug faced complex regulatory barriers, lack of awareness among healthcare professionals, and distribution inefficiencies. Without a structured GTM approach, the company risked delays, low prescription rates, and slow adoption.